• Skip to main content
  • Skip to footer

PeDRA

Pediatric Dermatology Research Alliance

  • DONATE
  • Pay 2022 Membership Dues
  • Join PeDRA
  • Login
MENUMENU
  • Contact Us
  • For Patients & Families
        • Patient Support
        • Patient Education
        • Community Spotlight
        • Clinical Trials
        • Patient Advisory Committee
        • Find a Pediatric Dermatologist (from SPD)
        • Parents, advocates, and patients over the age of 18 with a direct connection or significant interest in childhood skin disease or pediatric dermatology research are encouraged to join the PeDRA network for free as Community Members.

          Apply Now!

  • Education and Events
        • Virtual Education
        • Points of Discussion Podcast
        • Mentorship Program
        • Education Archive
        • 2022 PeDRA Annual Conference
        • Early Investigator Support
        • Dash for Discovery Fun Run/Walk
        • Events Calendar
        • Subscribe to the PeDRA Pearls Podcast channel on iTunes, Google Podcasts, or Spotify.

  • Research
        • Grants & Awards
        • Resources for Researchers
        • Survey Application
        • Study Application
        • Research Areas
        • Publications
        • Clinical Trials
        • 2022 Childhood Eczema Challenge Grant applications are now being accepted with a June 1st deadline.

  • About
        • Mission & Vision
        • Leadership & Staff
        • Annual Reports & Financials
        • News Archive
        • Our Supporters
        • Our Membership
        • Our Committees
        • Getting to Know You
        • NOW HIRING! Explore current opportunities at PeDRA.

  • Member Login

Pharmacologic Characterization of NTI-001 as First-In-Class Gαq R183Q Mutant Small Molecule Inhibitor

April 6, 2022 By Katherine Devenport


Principal Investigator:

Naiem Issa, MD, PhD
University of Miami Leonard M. Miller School of Medicine

Overview:

Sturge-Weber Syndrome (SWS) is a rare disease where a mutation causes abnormal capillary malformations affecting the skin, eyes, and brain leading to disfiguring skin changes, visual disturbances, as well as seizures and intellectual disability. A pharmacologic treatment at the root of SWS, the GNAQ (Gq) protein, is in critical need. Current drug development efforts have been focused on targeting proteins downstream of Gq. However, there is no small molecule drug that directly targets the Gq mutation causing SWS.

We discovered the drug NTI-001 to be the first small molecule inhibitor of Gq. This is a critical and historic milestone for not just SWS but also for G protein drug discovery at large as this is first-in-class and will serve as the framework for future drug discovery endeavors. Our proposal is to further assess NTI-001 as an inhibitor for the SWS-specific mutant of Gq known as the Gq R183Q mutant.

Status:

This project was funded by a 2021 PeDRA Research Grant.

Filed Under: Birthmark Studies

Footer

  • Our Membership
  • For Patients
  • For Researchers
  • Governance Policies
  • Financial Conflict of Interest Policy
  • Jobs at PeDRA
  • Facebook
  • Instagram
  • LinkedIn
  • Twitter
Sign up to receive emails from PeDRA
Join PeDRA
Donate

Copyright © 2022 · Pediatric Dermatology Research Alliance (PeDRA) · All Rights Reserved. · Privacy Policy